Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. - Wikidata - wikimedia - TriplyDB

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

http://www.wikidata.org/entity/Q37437544

about

Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Overview of advances in vasculogenic mimicry - a potential target for tumor therapy

P2860

Q49504547-4852AB38-BF38-443F-A8CB-03E13C8A9685 Q52645823-85AD2C48-CBDD-4D3D-85C5-9EFB7C18DA9E Q58803491-1BF2EADC-80D8-4B2D-8B4E-44AAAB4E9ACB

P2860

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

http://www.wikidata.org/entity/Q37437544

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

@en

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

@nl

type

label

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

@en

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

@nl

prefLabel

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

@en

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

@nl

P1433

Q37437544-14AD7ED9-DE1C-4FD5-AC3E-4650DD49AE2A

P1476

Q37437544-1AEACA9A-239B-4D17-BA19-D00F7072C7CF

P2093

Q37437544-013E124F-8B3D-485C-99AB-ECAC018AD14E

Q37437544-07FEA1F5-B753-4CFF-9799-701EBC18871C

Q37437544-1C1DA1E6-849E-4601-BD50-1FD9EF020A7F

Q37437544-237F89EB-7543-433A-996C-FB19C3891FEA

Q37437544-2D59E75F-77B2-4D15-A5E5-709C2055BAC5

Q37437544-4667DBB0-9EC3-43C0-9312-07E4CB9861CE

Q37437544-4DA1DA33-4CE5-4BD1-8F80-60514D0D874B

Q37437544-597C4D40-179E-4150-88D8-05937C641C8E

Q37437544-671DD0B7-C7F8-4AB5-8660-9E873D6A8427

Q37437544-7ECC82BD-E598-4C0E-BCBA-37C6BA53819B

P2860

Q37437544-04D962AF-46F4-416D-9686-F0F11A614287

Q37437544-05A219E3-C958-4238-B7BD-DD2C49E094A3

Q37437544-08CC380D-C11F-4248-B2F4-7A7FE67D3817

Q37437544-0A079B65-720E-4BA6-A61E-EF8B38B3BD1D

Q37437544-12A900EF-0430-4199-B667-EDF7A126015B

Q37437544-1760670B-61A6-44D3-BF13-78CC2A2CAE4A

Q37437544-23C759DF-0084-4F60-B5BF-1F91C8B67BF2

Q37437544-34474FEC-7D62-4F20-824B-79766E978D18

Q37437544-352EABE8-C74C-4151-A6B2-20C48824DD47

Q37437544-3623A42A-FAF6-4F3C-AF25-93E8D52C23C6

P304

Q37437544-EE284CA3-5338-461B-A6F6-2BA172A76F93

P31

Q37437544-4BEDA440-D2A6-4AF3-A70D-B03D965AAC26

P356

Q37437544-6A7AE6DA-B6B6-4F47-9130-D274B0AC1241

P407

Q37437544-992FF30F-66D0-4646-8AE3-E25AC65772AE

P433

Q37437544-5CC5DE01-99C1-4940-AADD-5F722DA2A464

P478

Q37437544-C072EF80-CB3F-485F-93F5-3D2B7A0FE8F0

P50

Q37437544-73C12AF5-8893-4895-A9A7-02799555AFA0

Q37437544-B6EAE810-2F7E-49E9-98E9-150FA0663FC1

Q37437544-F5C0EA97-0CD0-4213-9199-0DE8EE548BDD

P577

Q37437544-4A1FDB68-2B09-4146-BD98-E5A5D759AF54

P698

Q37437544-C1283B75-D56A-40A9-B820-B336974E0492

P932

Q37437544-8D84305B-48DE-40F6-9099-82C2F7E9964D

P356

ONCOTARGET.9542

P1433

P1476

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib

@en

P2093

Alfred Lopez

http://www.w3.org/2001/XMLSchema#string

Anne Janin

http://www.w3.org/2001/XMLSchema#string

Annemilaï Tijeras-Raballand

http://www.w3.org/2001/XMLSchema#string

Armand de Gramont

http://www.w3.org/2001/XMLSchema#string

Brad A Bryan

http://www.w3.org/2001/XMLSchema#string

Celia Dos Santos

http://www.w3.org/2001/XMLSchema#string

Dianne C Mitchell

http://www.w3.org/2001/XMLSchema#string

Eric Raymond

http://www.w3.org/2001/XMLSchema#string

Guilhem Bousquet

http://www.w3.org/2001/XMLSchema#string

Guillaume Gapihan

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model

Tumor cell vasculogenic mimicry: from controversy to therapeutic promise

HIF-1: mediator of physiological and pathophysiological responses to hypoxia

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Regulation of angiogenesis by hypoxia: role of the HIF system

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Tumor and endothelial cell hybrids participate in glioblastoma vasculature.

P304

38467-38486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9542

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Sandrine Faivre

Cindy Neuzillet

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27509260

http://www.w3.org/2001/XMLSchema#string

P932

5122404

http://www.w3.org/2001/XMLSchema#string